Uncommon of the Uncommon: Low-Grade Myelodysplastic Syndrome Evolving Into Chronic Myelogenous Leukemia

Zhang, Ling; Bennett, John M.; Zhang, Xiaohui; Moscinski, Lynn C.; Ibarz-Pinilla, Javier; List, Alan F.; Komrokji, Rami S.

doi:10.1200/jco.2010.31.6265

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2021

Publication Types

Select...

Article4

Other1

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 19 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A further literature search revealed a total of 22 cases of MDS with the Philadelphia chromosome. Details of patient characteristics are shown in Table 1, [8–25]. Patients with Philadelphia chromosome like mutations and patients with acquisition of the BCR-ABL gene at the time of evolution to acute leukemia have not been included in the table [26–28].…”

Section: Discussionmentioning

confidence: 99%

Philadelphia Translocation in MDS: A Case Report and a Brief Review of the Literature Looking at Its Prevalence, Disease Progression, and Treatment Options

Chelapareddy

Sen

2018

Case Reports in Hematology

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a group of clonal disorders characterized by ineffective and dysplastic hematopoiesis in the bone marrow with variable risk of progression to leukemia. MDS is characterized by specific karyotypic and molecular abnormalities. The t(9 : 22) Philadelphia translocation is not a common abnormality found in MDS, and it is not included in the prognostic indices for germline mutations. There are no definitive treatment guidelines for these patients either. Here, we reviewed previously reported cases of MDS with the Philadelphia translocation with a goal to determine their prognosis and treatment options, specifically the tyrosine kinase inhibitors (TKIs).

show abstract

Section: Discussionmentioning

confidence: 99%